Disphar

Disphar International is a pharmaceutical development company that specializes in the creation and licensing of generic and value-added oral solid dosage forms. Based in Hengelo, Netherlands, the company provides comprehensive services including formulation development, bioequivalence studies, and the preparation of regulatory dossiers. Disphar's business model is primarily focused on out-licensing its developed products to global pharmaceutical partners who then commercialize them under their own brands. The company was acquired by Mylan in 2008 and now operates as a subsidiary of Viatris following the 2020 merger of Mylan and Pfizer's Upjohn division. Disphar is recognized for its expertise in developing high-quality generic versions of widely used medications in therapeutic areas such as gastroenterology and bone health.